A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

The main inclusion criteria include but are not limited to: All participants: * Has a body mass index (BMI) between 18.0 and 42.0 kg/m\^2 Participants with hepatic impairment (HI): * Has a diagnosis of chronic, stable hepatic insufficiency at screening with features of cirrhosis Healthy volunteers: * Is medically healthy with no clinically significant medical history The main exclusion criteria include but are not limited to: All participants: * Has a history of gastrointestinal disease which may affect food and drug absorption * Has a history of cancer (malignancy) * Has a positive result for human immunodeficiency virus (HIV) * Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing Participants with HI: * Has had severe complications of liver disease within the preceding 3 months of screening * Has a history of recent (within 3 months prior to screening) variceal bleeds * Has evidence of hepatorenal syndrome * Is not in sufficient health, with regard to stability of HI, to undergo participation in the study with anticipated survival of \< 3 months * Has a history of liver or other solid organ transplantation * Has an active infection requiring systemic therapy * Requires paracentesis more often than 2 times per month * Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting * Has received antiviral and/or immune modulating therapy for hepatitis B virus (HBV) or hepatitis C virus (HCV) within 90 days prior to dosing * Is using HIV protease inhibitors * Is positive for Hepatitis B surface antigen (HBsAg) * Is positive for HCV Healthy volunteers: * Has positive results for HBsAg or HCV